Statins lower risk of advanced liver fibrosis in diabetes patients: Study

Italy: Statin use lowers the risk of cirrhosis and advanced liver fibrosis in type 2 diabetes (T2D) patients, finds a recent study in the journal Metabolism: Clinical and Experimental. The lower risk was specifically seen in younger patients and women.

Type 2 diabetes patients are at increased risk of both advanced liver fibrosis related to non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). Statin use is known to reduce the CVD incidence while evidence on its effect on NAFLD severity is limited. To fill this knowledge gap, Stefano Ciardullo and Gianluca Perseghin from Italy, performed a cross-sectional study performed using data from the 2017–2018 cycle of the National Health and Nutrition Examination Survey (NHANES).

It included adult patients with T2D and reliable vibration-controlled transient elastography (VCTE) results. Presence of liver fibrosis and steatosis were assessed by the median values of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) and, respectively. Patients with evidence of viral hepatitis and significant alcohol consumption were excluded.

The association between statin treatment and both steatosis and advanced (≥F3) liver fibrosis was evaluated using Logistic regression analysis after adjustment for potential confounders.

The study population consisted of 744 patients. 

"Given the absence of approved therapies for NAFLD-fibrosis, it would be reasonable to initiate specific randomized controlled trials with statins," wrote the authors. 

The study titled, "Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes," is published in the journal Metabolism: Clinical and Experimental.

DOI: https://www.metabolismjournal.com/article/S0026-0495(21)00052-4/fulltext